Somatostatin receptor subtype gene expression in pituitary adenomas.

Somatostatin (SRIF) exerts its diverse biological effects through a family of membrane receptors. In addition to inhibiting GH secretion, SRIF has antiproliferative effects and has been used clinically in the treatment of pituitary tumors. SRIF receptor (SSTR) expression has recently been identified in pituitary adenomas, and it is unknown whether differential expression of SSTR subtypes predicts clinical responses to SRIF analogs. We therefore determined which SSTR subtype messenger RNAs (mRNAs) are expressed in pituitary adenoma phenotypes and in normal human pituitary tissue using reverse transcriptase-polymerase chain reaction and tested whether expression of specific SSTR subtype mRNA is necessary for SRIF inhibition of GH secretion in human somatotroph adenomas in vitro. Expression of SSTR subtypes 1, 2, and 5 mRNA was identified in all pituitary adenoma types and normal pituitary tissue. In contrast, SSTR3 mRNA was detected in only one somatotroph adenoma as well as in control insulinoma tissue, a tissue known to express SSTR3 mRNA, and was not detected in normal pituitary tissue. SSTR4 mRNA was not detected in any human pituitary tissue. To determine whether specific SSTR subtype mRNA expression is required for SRIF inhibition of GH secretion, five somatotroph adenomas were treated with 10(-7) mol/L SRIF in vitro, and significant inhibition of GH release occurred in all adenomas. All five tumors expressed SSTR2 mRNA and SSTR5 mRNA, and three expressed SSTR1 mRNA. The absence of SSTR1 mRNA expression did not affect the ability of SRIF to suppress GH secretion. We conclude that: 1) human pituitary adenomas and normal pituitary express multiple SSTR gene transcripts; 2) SSTR5 mRNA, which has not been reported in other human endocrine tumor types, is expressed in neoplastic and normal pituitary tissue; and 3) SSTR2 mRNA, SSTR5 mRNA, and variable SSTR1 mRNA are expressed in GH-secreting tumors, which are responsive to SRIF in vitro. Further understanding of SSTR gene expression in pituitary adenomas will facilitate our understanding of the pathogenetic mechanisms of tumorigenesis and may provide a rationale for the use of specific SRIF analogs for clinical application.

[1]  G. Bell,et al.  Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.

[2]  S. Melmed,et al.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. , 1994, The Journal of clinical endocrinology and metabolism.

[3]  A. Klibanski,et al.  Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro. , 1994, The Journal of clinical investigation.

[4]  G. Bell,et al.  Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  H. Niznik,et al.  Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. , 1994, Molecular pharmacology.

[6]  S. Seino,et al.  Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. , 1994, The Journal of clinical investigation.

[7]  C. B. Srikant,et al.  Expression of multiple somatostatin receptor genes in AtT-20 cells. Evidence for a novel somatostatin-28 selective receptor subtype. , 1994, The Journal of biological chemistry.

[8]  H. Imura,et al.  Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. , 1993, Biochemical and biophysical research communications.

[9]  M. Berelowitz,et al.  Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. , 1993, Biochemical and biophysical research communications.

[10]  S. Law,et al.  Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. , 1993, The Journal of biological chemistry.

[11]  G. Bell,et al.  Molecular biology of somatostatin receptors , 1993, Trends in Neurosciences.

[12]  S. Seino,et al.  Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. , 1992, Molecular endocrinology.

[13]  D. Schoenfeld,et al.  Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. , 1992, The Journal of clinical endocrinology and metabolism.

[14]  S. Law,et al.  Pharmacological properties of two cloned somatostatin receptors. , 1992, Molecular pharmacology.

[15]  A. Klibanski,et al.  Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. , 1991, The Journal of clinical endocrinology and metabolism.

[16]  E. Krenning,et al.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors. , 1991, Endocrine reviews.

[17]  A. Harris,et al.  Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. , 1991, Archives of internal medicine.

[18]  D. Wynick,et al.  Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. , 1991, The Journal of clinical endocrinology and metabolism.

[19]  B. Evers,et al.  Somatostatin and analogues in the treatment of cancer. A review. , 1991, Annals of surgery.

[20]  A. Bogdén,et al.  Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. , 1990, Cancer research.

[21]  E. Hedley‐Whyte,et al.  Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study. , 1989, The American journal of pathology.

[22]  U. Plöckinger,et al.  Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. , 1989, The Journal of clinical endocrinology and metabolism.

[23]  J. Reubi,et al.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. , 1989, The Journal of clinical endocrinology and metabolism.

[24]  A. Schally,et al.  Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Mahy,et al.  Pertussis toxin modifies the characteristics of both the inhibitory GTP binding proteins and the somatostatin receptor in anterior pituitary tumor cells. , 1988, The Journal of pharmacology and experimental therapeutics.

[26]  A. Bogdén,et al.  In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. , 1988, Biochemical and biophysical research communications.

[27]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[28]  J. Avruch,et al.  Insulin regulation of protein biosynthesis in differentiated 3T3 adipocytes. Regulation of glyceraldehyde-3-phosphate dehydrogenase. , 1985, The Journal of biological chemistry.

[29]  G. Schultz,et al.  A nucleotide regulatory site for somatostatin inhibition of adenylate cyclase in S49 lymphoma cells , 1983, Nature.

[30]  B. Weintraub,et al.  Alpha and beta subunits of human thyrotropin: purification and development of specific radioimmunoassays. , 1974, Endocrinology.

[31]  S. Melmed,et al.  Somatostatin Receptor Subtypes in Pituitary Tumors , 1996 .

[32]  P. Black,et al.  Dopaminergic Regulation of a-Subunit Secretion and Messenger Ribonucleic Acid Levels in a-Secreting Pituitary Tumors* , 1988 .